Director Dealings

Alliance Pharma PLC

19 July 2023

 

19 July 2023

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Director Dealings

Alliance Pharma plc (AIM: APH), the international healthcare group, has been notified that Andrew Franklin, the Chief Financial Officer of the Company, purchased 50,988 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 49.005 pence per share on 18^th July 2023; and Richard Jones, a non-executive Director of the Company, purchased 53,000 Ordinary Shares at a price of 47.10 pence per share on 18^th July 2023.

Following this transaction, (i) Mr. Franklin's total beneficial interest in the Company is 179,372 Ordinary Shares, representing 0.03% of the Company's issued share capital; and (ii) Mr. Jones' total beneficial interest in the Company is 68,000 Ordinary Shares, representing 0.013% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Andrew Franklin
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma Plc
b)	Legal Entity Identifier	213800RYIWZA4Q5WPZ13
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each GB0031030819
b)	Nature of the transaction	Purchase of shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		49.005	50,988
e)	Aggregated information - Aggregated volume - Price - Aggregated total	50,988 Ordinary Shares, bought at a price of 49.005 pence per share, totalling £24,986.67
f)	Date of the transaction	18 July 2023
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Richard Jones
2	Reason for the notification
a)	Position/status	Non Executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma Plc
b)	Legal Entity Identifier	213800RYIWZA4Q5WPZ13
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each GB0031030819
b)	Nature of the transaction	Purchase of shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		47.10	53,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	53,000 Ordinary Shares, bought at a price of 47.10 pence per share, totalling £24,963
f)	Date of the transaction	18 July 2023
g)	Place of the transaction	London Stock Exchange, AIM

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
[e-mail]
Numis Securities Limited (Nominated Adviser and Joint Broker)	+ 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker)	+ 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END